European malaria vaccine initiative: Portfolio and perspectives for the future

Human Vaccines

Volumn 6, Issue 1, 2010, Pages

  Imoukhuede, Egeruan Babatunde ^a   Ventura, Roland ^a   Imbault, Nathalie ^a   Van Schooten, Harry ^a   Leroy, Odile ^a  

^a European Malaria Vaccine Initiative ^*

Author keywords

Development; Formulation; Malaria; Perspectives; Portfolio; Research; Vaccine

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; APICAL MEMBRANE ANTIGEN 1; CIRCUMSPOROZOITE PROTEIN; ERYTHROCYTE BINDING ANTIGEN 175; GLUTAMATE RICH PROTEIN; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 3; MONTANIDE ISA 51; MONTANIDE ISA 720; P27A ANTIGEN; UNCLASSIFIED DRUG;

CLINICAL RESEARCH; CLINICAL TRIAL; DRUG FORMULATION; EUROPE; HUMAN; MALARIA; REVIEW; VACCINE PRODUCTION; COOPERATION; IMMUNOLOGY; ORGANIZATION AND MANAGEMENT; PLASMODIUM; TRANSLATIONAL RESEARCH;

CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; EUROPE; HUMANS; MALARIA; MALARIA VACCINES; PLASMODIUM; TRANSLATIONAL RESEARCH;

EID: 85046915276     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.1.9603     Document Type: Review

References (23)

1. EMVI annual report 2009; (www.emvi.org/ annual+reports).
2. Roestenberg M, Remarque E, de Jonge E, Hermsen R, Blythman H, Leroy O, et al. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS ONE 2008; 3:3960.
3. Faber BW, Remarque EJ, Kocken CH, Cheront P, Cingolani D, Xhonneux F, et al. Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris. Vaccine 2008; 26:6143-50.
4. Remarque EJ, Faber BW, Kocken CH, Thomas AW. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect Immun 2008; 76:2660-70.
5. Remarque EJ, Faber BW, Kocken CH, Thomas AW. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol 2008; 24:74-84.
6. Faber BW, Remarque EJ, Morgan WD, Kocken CH, Holder AA, Thomas AW. Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1. Infect Immun 2007; 75:5947-55.
7. Igonet S, Vulliez-Le Normand B, Faure G, Riottot MM, Kocken CH, Thomas AW, Bentley GA. Cross-reactivity studies of an anti-Plasmodium vivax apical membrane antigen 1 monoclonal antibody: binding and structural characterisation. J Mol Biol 2007; 366:1523-37.
8. Langermans JA, Hensmann M, van Gijlswiik M, Zhang D, Pan W, Giersing BK, et al. Preclinical evaluation of a chimeric malaria vaccine candidate in Montanide ISA 720: immunogenicity and safety in rhesus macaques. Hum Vaccin 2006; 2:222-6.
9. Pizarro JC, Vulliez-Le Normand B, Chesne-Seck ML, Collins CR, Withers-Martinez C, Hackett F, et al. Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science 2005; 308:408-11.
10. Rodrigues MH, Rodrigues KM, Oliveira TR, Cômodo AN, Rodrigues MM, Kocken CH, et al. Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1. Int J Parasitol 2005; 35:185-92.
11. Polley SD, Mwangi T, Kocken CH, Thomas AW, Dutta S, Lanar DE, et al. Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 2004; 23:718-28.
12. Vulliez-Le Normand B, Pizarro JC, Chesne-Seck ML, Kocken CH, Faber B, Thomas AW, Bentley GA. Expression, crystallization and preliminary structural analysis of the ectoplasmic region of apical membrane antigen 1 from Plasmodium vivax, a malaria-vaccine candidate. Acta Crystallogr D Biol Crystallogr 2004; 60:2040-3.
13. Hermsen CC, Verhage DF, Telgt DS, Teelen K, Bousema JT, Roestenberg M, et al. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine 2007; 25:2930-40. Epub 2006.
14. Theisen M, Soe S, Brunstedt K, Follmann F, Bredmose L, Israelsen H, et al. A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. Vaccine 2004; 22:1188-98.
15. Pattnaik P, Shakri AR, Singh S, Goel S, Mukherjee P, Chitnis CE. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175. Vaccine 2007; 25:806-13.
16. Mamillapalli A, Pattnaik P, Sharma M, Sharma SK, Tyagi PK, Joshi H, Chitnis CE. Sequence polymorphisms in the receptor-binding domain of Plasmodium falciparum EBA-175: implications for malaria vaccine development. Mol Biochem Parasitol 2006; 146:120-3.
17. Yazdani SS, Shakri AR, Chitnis CE. A high cell density fermentation strategy to produce recombinant malarial antigen in E. coli. Biotechnol Lett 2004; 26:1891-5.
18. Pandey KC, Singh S, Pattnaik P, Pillai CR, Pillai U, Lynn A, et al. Bacterially expressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies. Mol Biochem Parasitol 2002; 123:23-33.
19. Draper SJ, Moore AC, Goodman AL, Long CA, Holder AA, Gilbert SC, et al. Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 2008; 14:819-21.
20. Villard V, Agak GW, Frank G, Jafarshad A, Servis C, Nébié I, et al. Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif. PLoS ONE 2007; 2:645.
21. Corradin G, Villard V, Kajava AV. Protein structure based strategies for antigen discovery and vaccine development against malaria and other pathogens. Endocr Metab Immune Disord Drug Targets 2007; 7:259-65.
22. Malaria Vaccine Technology Roadmap (www.malariavaccineroadmap.net/).
23. EMVI strategy plan (www.emvi.org/emvi+strategy).